MANAGING INFLUENZA: AMANTADINE, RIMANTADINE AND BEYOND

Autor:	D M, Fleming
Rok vydání:	2001
Předmět:	Adult Adolescent Infant Neuraminidase General Medicine Middle Aged Antiviral Agents Guanidines Influenza B virus Rimantadine Influenza A virus Influenza Vaccines Child Preschool Influenza Human Amantadine Sialic Acids Humans Zanamivir Child Aged Pyrans
Zdroj:	International Journal of Clinical Practice. 55:189-195
ISSN:	1742-1241 1368-5031
Popis:	Amantadine and rimantadine are effective in the treatment and prophylaxis of influenza A. Neither drug, however, has achieved widespread acceptance because of the rapid development of viral resistance, their lack of activity against influenza B and, in the case of amantadine, adverse events. Complete cross-resistance occurs with these compounds and is associated with a single nucleotide change in the M2 protein. Resistant variants are transmissible and fully pathogenic. Zanamivir is the first widely approved neuraminidase inhibitor for the treatment of influenza. It is delivered directly to the primary site of viral replication, the respiratory tract, and is well tolerated and effective in the treatment of both influenza A and B. Data in prophylaxis are also encouraging. During the extensive clinical programme no evidence for the emergence of drug-resistant strains with acute therapy was found. Zanamivir represents a significant advance over older agents in the management of influenza A and B.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32b8ad3a6d69c0dfffcfc76a723ba6d https://doi.org/10.1111/j.1742-1241.2001.tb11012.x Zobrazit plný text záznamu